Fabry Disease Market 2020 Pipeline Analysis, Opportunities And Forecast to 2025

Wiseguyreports.Com Adds “Fabry Disease -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025” To Its Research Database

PUNE, MAHARASHTRA, INDIA, October 27, 2020 /EINPresswire.com/ -- Fabry Disease Industry

Description

Wiseguyreports.Com Adds “Fabry Disease -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025” To Its Research Database

Fabry Disease (also known as Anderson Fabry Disease) is a progressive X linked inherited genetic disorder of glycosphingolipid metabolism due to deficient or absent lysosomal α-galactosidase A activity. It is a devastating inborn error of metabolism with, particularly in the early stages, being played by cellular dysfunction and microvascular pathology being induced by lysosomal glycosphingolipid deposition. The absence or deficient activity of lysosomal exoglycohydrolase α-galactosidase A results in the progressive accumulation of globotriaosylceramide and related glycosphingolipids within lysosomes which are ubiquitous subcellular organelles.

The first clinical symptoms interfering with the child's well-being and performance arise in childhood, typically between the ages of 3 and 10 years, and generally a few years later in girls than in boys. With age, progressive damage to vital organ systems develops in both genders leading to organ failure. End-stage renal disease and life-threatening cardiovascular or cerebrovascular complications limit life-expectancy. The clinical signs are multisystemic, heterogeneous, and progressive.

Request For Sample Report @ https://www.wiseguyreports.com/sample-request/5762578-fabry-disease-pipeline-analysis-2019

The biochemical diagnosis of Fabry Disease is established by measuring α-gal A activity in plasma or leukocytes taken from peripheral blood, cultured fibroblasts or using the samples extracted from the filter paper blood spots. The diagnosis of FD can arise from careful clinical and instrumental investigations, together with family history data and accurate interpretation of genetic and enzymatic analyses. Identification of a hemizygous GLA pathogenic variant by molecular genetic testing confirms the diagnosis in a male proband.

The therapeutic pipeline of Fabry Disease consists of approximately 9+ products in different stages of development. Currently, 2+ drugs are in Phase III development and major drugs are in pre-clinical stage.

Top Company Analysed

Some of the key players include Amicus Therapeutics; Evotec; Freeline; Greenovation Biotech; Idorsia Pharmaceuticals; Moderna; Pharming; Protalix Biotherapeutics; Resverlogix Corp; Sangamo Therapeutics and Sanofi Genzyme.

Scope of the report:

• Provides an overview of therapeutic pipeline activity for Fabry Disease across the complete product development cycle including all clinical and non-clinical stages
• The report comprises of detailed profiles of Fabry Disease therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
• Detailed profiles of the dormant products have been included in the report

Leave a Query @ https://www.wiseguyreports.com/enquiry/5762578-fabry-disease-pipeline-analysis-2019

Reasons to buy:

• The Fabry Disease pipeline presents the detailed profile of drugs. The analysis offered in the report is a combination of deep dive secondary research and input from Key Opinion Leader of the industry
• The report presents a quick review of the current scenario regarding the drug development of the indication at one glance
• The report covers in-depth analysis of prominent industry peers with a primary focus on company consolidation, designation, technology, agreements and patents regarding the therapy
• Detailed examination on diagnosis, treatment and guidelines prevailing in the industry
• Examination of industry attractiveness with the help of launch timelines
• The study comprehensively covers the market across drugs in different phases of development
• Extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued products

Customization Options:

The Fabry Disease pipeline analysis report can be customized to the country level or any other competitive segment. Besides this, UMI understands that you may have your own business need, hence we also provide fully customized solutions to clients.

Table of Content

1. REPORT INTRODUCTION

2. DISEASE OVERVIEW 9

3. PIPELINE THERAPEUTICS AT A GLANCE 38

4. COMPARATIVE ANALYSIS 39

5. LATE PHASE PRODUCTS (PHASE III) 40

6. MID PHASE PRODUCTS (PHASE II) 50

7. EARLY STAGE PRODUCTS (PHASE I) 53

8. PRE-CLINICAL STAGE PRODUCTS 58

9. THERAPEUTIC ASSESSMENT 65

10. APPROVAL TIMELINES 70

11. ANALYST INSIGHTS 71

12. INACTIVE PRODUCTS 72

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=5762578

Continued...           

Contact Us: Sales@Wiseguyreports.com Ph: +1-646-845-9349 (Us)  Ph: +44 208 133 9349 (Uk)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349
email us here